Vaccine maker stocks fall as Trump chooses RFK Jr. to lead HHS
Shares of vaccine makers fell as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Services. Health policy experts have said a second Trump term could allow Kennedy to elevate anti-vaccine rhetoric.
Vaccine makers fall after Trump nominates RFK to head HHS
BioNTech (BNTX), Pfizer (PFE), Novavax (NVAX), Vaxcyte (PCVX) and GSK (GSK) moved lower at the end of the trading day following reports that President-elect Donald Trump Donald Trump would nominate noted vaccine skeptic Robert F.
Moderna, Pfizer Stocks Fall After Reports of RFK Jr. Nomination
Shares of vaccine-makers fell after reports that Donald Trump is expected to nominate vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services. Shares of Moderna (MRNA
Trump will nominate RFK Jr. for HHS secretary
Washington — President-elect Donald Trump said Thursday in a social media post that he'll nominate Robert F. Kennedy Jr. to lead the Department of Health and Human Services. "I am thrilled to announce Robert F.
Trump Selects RFK Jr. for Health Secretary; Vaccine Stocks Fall
President-elect Donald Trump said he’s tapping Robert F. Kennedy Jr., to run the Department of Health and Human Services, a move that would elevate a prominent vaccine skeptic and pharmaceutical industry critic to a top role on federal health policy.
Is RFK Jr. Anti-Vaccine? Everything the HHS Secretary Nominee Has Said
Kennedy has been nominated to lead the federal government's health agency—what does this mean for vaccine access in the U.S.?
Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS
Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and former presidential hopeful Robert F. Kennedy Jr. as his pick to lead the U.
BioNTech buys China's Biotheus to support oncology strategy
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain ...
Investor's Business Daily on MSN11h
BioNTech Stock Got A IBD RS Rating Lift
How Much Money To Invest Now. Is BioNTech Stock A Buy? BioNTech stock is building a consolidation with a 131.49 buy point.
GlobalData on MSN22h
BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
FierceBiotech2d
BioNTech pays $800M to take control of potential Keytruda killer
BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus ...
The Analyst Landscape: 17 Takes On BioNTech
Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
STAT1d
BioNTech acquires its Chinese cancer drug partner
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
Strategic Acquisition and Oncology Focus Justify BioNTech’s Buy Rating
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
AOL1d
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
BioPharma Dive1d
BioNTech to buy Biotheus, gaining control of cancer bispecific
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
BioNTech strikes $950mn deal for Chinese drugmaker Biotheus
BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...
BioNTech To Buy Biotheus In Upfront Payment Of $800 Mln
BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company ...
BioNTech (NASDAQ:BNTX) Raised to “Buy” at The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...